colorectal cancer
Conditions
Interventions
case series:Nil
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) They voluntarily participated in the study and signed a written informed consent; (2) 18-75 years old patients; (3) Histologically confirmed colorectal cancer; (4) Metastatic lesions appeared for the first time, but radical resection was impossible; (5) The status of Ras and BRAF genes in tumor tissue was clear; (6) CT or MRI confirmed that at least one measurable lesion met RECIST 1.1 standard; (7) The estimated survival time was at least 12 weeks; (8) The ECoG score of physical condition was 0-1; (9) Sufficient important organ function (Hematology, liver and kidney function, etc.);
Exclusion criteria
Exclusion criteria: (1) They had received chemotherapy for CRC in the past, except for adjuvant treatment which was over 9 months (including oxaliplatin / irinotecan) before the start of the study, and the end of adjuvant therapy > 6 months (without oxaliplatin / irinotecan); (2) Radiotherapy or surgery was performed within 30 days before treatment; (3) He had previously received monoclonal antibody therapy, VEGF pathway targeting therapy, EGFR pathway targeting therapy or other signal transduction pathway inhibitors; (4) Ovious cavity or necrosis in the tumor; (5) Poor control of infection; (6) Poor control of serous cavity effusion; (7) Have a clear history of neurological or mental illness, including epilepsy or dementia; (8) Other exclusion criteria refer to clinical study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tregs cell value;DFS; | — |
Countries
China
Contacts
Public ContactChuan Liu
Shanghai General Hospital
Outcome results
None listed